CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Sonoma Pharma - SNOA CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 1.58-5.56
Average Volume (10 days) 0.05295
Average Volume (3 months) 15.4209
Market Cap 5.27505
P/E Ratio N/A
Shares Outstanding 3102970
Revenue 12.514
EPS -1.87293
Dividend (Yield %) N/A
Beta 0.94651
Next Earnings Date Feb 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Sonoma Pharma Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Total revenue 12.825 16.658 18.97 17.928 18.629 12.628
Revenue 12.825 16.658 18.97 17.928 18.629 12.628
Cost of Revenue, Total 7.157 9.348 10.09 9.806 11.847 8.417
Gross Profit 5.668 7.31 8.88 8.122 6.782 4.211
Total Operating Expense 25.799 30.847 30.228 25.318 22.078 17.792
Selling/General/Admin. Expenses, Total 17.066 19.924 18.62 14.173 9.453 9.755
Research & Development 1.576 1.575 1.518 1.339 0.555 0.125
Operating Income -12.974 -14.189 -11.258 -7.39 -3.449 -5.164
Interest Income (Expense), Net Non-Operating 0.019 0.218 0.157 0.034 0.004 -0.01
Other, Net 0.018 -0.307 -0.239 0.24 -0.594 -0.394
Net Income Before Taxes -12.937 -14.278 -11.34 -3.544 -3.902 -5.418
Net Income After Taxes -8.669 -14.328 -11.798 -3.573 -4.615 -5.086
Net Income Before Extra. Items -8.669 -14.328 -11.798 -3.573 -4.615 -5.086
Total Extraordinary Items 17.943 0.265 0.665 0
Net Income 9.274 -14.328 -11.798 -3.308 -3.95 -5.086
Income Available to Common Excl. Extra. Items -8.669 -14.328 -11.798 -3.573 -4.615 -5.086
Income Available to Common Incl. Extra. Items 9.274 -14.328 -11.798 -3.308 -3.95 -5.086
Diluted Net Income 9.274 -14.328 -11.798 -3.308 -3.95 -5.086
Diluted Weighted Average Shares 0.46933 0.503 0.924 1.477 1.996 2.653
Diluted EPS Excluding Extraordinary Items -18.4711 -28.4851 -12.7684 -2.41909 -2.31212 -1.91708
Diluted Normalized EPS -18.4711 -28.4851 -12.7684 -3.99106 -2.28412 -2.07755
Gain (Loss) on Sale of Assets 3.572 0.137 0.15
Unusual Expense (Income) 0.223 -0.505
Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022
Total revenue 2.157 3.684 3.744 2.902 2.298
Revenue 2.157 3.684 3.744 2.902 2.298
Cost of Revenue, Total 2.397 2.001 2.509 1.685 2.222
Gross Profit -0.24 1.683 1.235 1.217 0.076
Total Operating Expense 4.971 4.588 4.708 3.86 4.635
Selling/General/Admin. Expenses, Total 2.49 2.273 2.195 2.135 3.152
Research & Development 0.13 0.084 0.01 0.026 0.004
Unusual Expense (Income) -0.046 0.23 -0.006 0.014 -0.743
Operating Income -2.814 -0.904 -0.964 -0.958 -2.337
Interest Income (Expense), Net Non-Operating 0.002 -0.001 -0.004 0.003 -0.009
Gain (Loss) on Sale of Assets 0 0 0.15 0 0
Other, Net 0.093 -0.193 0.723 0.011 -0.936
Net Income Before Taxes -2.719 -1.098 -0.095 -0.944 -3.282
Net Income After Taxes -3.432 -1.098 -0.1 -0.944 -2.944
Net Income Before Extra. Items -3.432 -1.098 -0.1 -0.944 -2.944
Total Extraordinary Items -0.228 0 0 0 0
Net Income -3.66 -1.098 -0.1 -0.944 -2.944
Income Available to Common Excl. Extra. Items -3.432 -1.098 -0.1 -0.944 -2.944
Income Available to Common Incl. Extra. Items -3.66 -1.098 -0.1 -0.944 -2.944
Diluted Net Income -3.66 -1.098 -0.1 -0.944 -2.944
Diluted Weighted Average Shares 2.083 2.093 2.344 3.08 3.091
Diluted EPS Excluding Extraordinary Items -1.64762 -0.52461 -0.04266 -0.30649 -0.95244
Diluted Normalized EPS -1.66198 -0.41472 -0.08592 -0.30195 -1.10869
Dividends per Share - Common Stock Primary Issue 0 0 0
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Total Current Assets 22.643 16.254 12.496 12.283 12.983 16.43
Cash and Short Term Investments 17.461 10.066 3.689 3.691 4.22 7.396
Cash & Equivalents 17.461 10.066 3.689 3.691 4.22 7.396
Total Receivables, Net 2.108 1.752 4.444 5.278 4.656 4.778
Accounts Receivable - Trade, Net 2.108 1.537 3.481 3.973 2.806 2.407
Total Inventory 2.221 2.865 3.409 2.181 2.53 2.663
Prepaid Expenses 0.616 1.332 0.731 0.951 1.368 1.375
Other Current Assets, Total 0.237 0.239 0.223 0.182 0.209 0.218
Total Assets 25.459 19.206 14.448 14.561 14.987 18.845
Property/Plant/Equipment, Total - Net 1.239 1.136 0.727 0.724 1.129 0.879
Property/Plant/Equipment, Total - Gross 4270 4.706 4.641 4.326 2.6 2.59
Accumulated Depreciation, Total -3031 -3.57 -3.914 -3.602 -1.471 -1.711
Other Long Term Assets, Total 1.577 1.816 1.225 1.554 0.875 1.536
Total Current Liabilities 3.288 3.261 3.591 4.729 4.078 5.819
Accounts Payable 1.255 1.272 1.255 2.067 1.769 1.641
Accrued Expenses -540.698 1.023 1.236 1.446 1.027 1.309
Notes Payable/Short Term Debt 0 0 0 0 0 0.688
Current Port. of LT Debt/Capital Leases 0.197 0.377 0.463 0.481 0.596 0.12
Other Current Liabilities, Total 542.534 0.589 0.637 0.735 0.686 2.061
Total Liabilities 4.028 3.88 3.959 8.937 9.624 10.148
Total Long Term Debt 0.213 0.176 0.012 0 1.31 0
Long Term Debt 0.045 0.032 0.012 0 1.31 0
Capital Lease Obligations 0.168 0.144 0
Other Liabilities, Total 0.527 0.443 0.356 4.208 4.236 4.329
Total Equity 21.431 15.326 10.489 5.624 5.363 8.697
Preferred Stock - Non Redeemable, Net 0 0 0 0 0 0
Common Stock 0.001 0.001 0.002 0.002 0.002 0.002
Additional Paid-In Capital 168.709 176.74 184.074 186.559 189.217 197.37
Retained Earnings (Accumulated Deficit) -143.101 -157.44 -169.238 -175.327 -179.277 -184.363
Other Equity, Total -4.178 -3.975 -4.349 -5.61 -4.579 -4.312
Total Liabilities & Shareholders’ Equity 25.459 19.206 14.448 14.561 14.987 18.845
Total Common Shares Outstanding 0.47659 0.68575 1.31634 1.77748 2.09291 3.10094
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 12.983 12.157 18.021 17.699 16.43
Cash and Short Term Investments 4.22 2.811 8.392 8.529 7.396
Cash & Equivalents 4.22 2.811 8.392 8.529 7.396
Total Receivables, Net 2.806 2.998 3.416 2.854 2.407
Accounts Receivable - Trade, Net 2.806 2.998 3.416 2.854 2.407
Total Inventory 2.53 2.62 2.482 2.879 2.663
Prepaid Expenses 3.218 3.509 3.519 3.226 3.746
Other Current Assets, Total 0.209 0.219 0.212 0.211 0.218
Total Assets 14.987 14.121 19.828 19.347 18.845
Property/Plant/Equipment, Total - Net 1.129 1.095 1.037 0.922 0.879
Other Long Term Assets, Total 0.875 0.869 0.77 0.726 1.536
Total Current Liabilities 4.078 5.233 4.078 3.875 5.819
Accounts Payable 1.769 1.831 1.876 1.583 1.641
Accrued Expenses 1.394 1.456 1.263 1.553 2.093
Notes Payable/Short Term Debt 0 0.397 0.199 0 0.688
Current Port. of LT Debt/Capital Leases 0.596 1.31 0.587 0.587 0.12
Other Current Liabilities, Total 0.319 0.239 0.153 0.152 1.277
Total Liabilities 9.624 9.5 8.368 8.178 10.148
Total Long Term Debt 1.31 0 0 0 0
Long Term Debt 1.31 0 0 0 0
Other Liabilities, Total 4.236 4.267 4.29 4.303 4.329
Total Equity 5.363 4.621 11.46 11.169 8.697
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.002 0.002 0.003 0.003 0.002
Additional Paid-In Capital 189.217 189.266 196.438 197.156 197.37
Retained Earnings (Accumulated Deficit) -179.277 -180.375 -180.475 -181.419 -184.363
Other Equity, Total -4.579 -4.272 -4.506 -4.571 -4.312
Total Liabilities & Shareholders’ Equity 14.987 14.121 19.828 19.347 18.845
Total Common Shares Outstanding 2.09291 2.09291 3.00474 3.09934 3.10094
  • Annual
  • Quarterly
2017 2018 2019 2020 2021 2022
Net income/Starting Line -8.669 -14.328 -11.798 -2.946 -3.95 -5.086
Cash From Operating Activities -8.167 -12.439 -11.717 -4.591 -3.378 -4.248
Cash From Operating Activities 0.248 0.49 0.453 0.312 0.227 0.186
Non-Cash Items 4.779 3.151 0.894 -0.398 -1.039 -1.873
Cash Interest Paid 0.003 0.04 0.033 0.016 0.012 0.024
Changes in Working Capital -4.525 -1.752 -1.266 -1.559 1.384 3.354
Cash From Investing Activities 18.224 -0.201 -0.131 3.644 0.388 -0.099
Capital Expenditures -0.394 -0.187 -0.1 -0.206 -0.179 -0.137
Other Investing Cash Flow Items, Total 18.618 -0.014 -0.031 3.85 0.567 0.038
Cash From Financing Activities -0.032 5.24 5.492 1.029 3.308 7.396
Issuance (Retirement) of Stock, Net 0.098 5.52 5.97 1.376 2.287 7.77
Issuance (Retirement) of Debt, Net -0.13 -0.28 -0.478 -0.347 1.021 -0.374
Foreign Exchange Effects -0.033 0.005 -0.021 -0.08 0.211 0.127
Net Change in Cash 9.992 -7.395 -6.377 0.002 0.529 3.176
Cash Taxes Paid 0.941 0.767
Deferred Taxes -0.829
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -3.95 -1.098 -1.198 -2.142 -5.086
Cash From Operating Activities -3.378 -1.223 -2.527 -2.853 -4.248
Cash From Operating Activities 0.227 0.048 0.1 0.137 0.186
Non-Cash Items -1.039 0.059 -0.609 -0.703 -1.873
Cash Interest Paid 0.012 0.004 0.008 0.012 0.024
Changes in Working Capital 1.384 -0.232 -0.82 -0.145 3.354
Cash From Investing Activities 0.388 -0.049 -0.038 -0.038 -0.099
Capital Expenditures -0.179 -0.049 -0.074 -0.075 -0.137
Other Investing Cash Flow Items, Total 0.567 0 0.036 0.037 0.038
Cash From Financing Activities 3.308 -0.209 6.711 7.174 7.396
Issuance (Retirement) of Stock, Net 2.287 0 7.108 7.77 7.77
Issuance (Retirement) of Debt, Net 1.021 -0.199 -0.397 -0.596 -0.374
Foreign Exchange Effects 0.211 0.072 0.026 0.026 0.127
Net Change in Cash 0.529 -1.409 4.172 4.309 3.176
Financing Cash Flow Items -0.01
Deferred Taxes -0.829
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Renaissance Technologies LLC Hedge Fund 2.4289 75367 -400 2022-09-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1885 36878 0 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.0962 34014 0 2022-09-30 LOW
Citadel Advisors LLC Hedge Fund 0.592 18369 -7308 2022-09-30 HIGH
Birnbaum (Jay E) Individual Investor 0.185 5739 0 2022-07-22 LOW
UBS Financial Services, Inc. Investment Advisor 0.1775 5507 4837 2022-09-30 LOW
McLaughlin (Jerry G.) Individual Investor 0.1745 5414 0 2022-07-22 LOW
Tower Research Capital LLC Hedge Fund 0.1583 4911 4388 2022-09-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.0927 2875 0 2022-09-30 LOW
Thornton (Bruce) Individual Investor 0.0266 825 0 2022-07-22 LOW
U.S. Bancorp Asset Management, Inc. Investment Advisor 0.0161 500 0 2022-09-30 LOW
Advisor Group, Inc Investment Advisor 0.0053 166 0 2022-09-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.0028 86 0 2022-09-30 LOW
Rockefeller Capital Management Investment Advisor 0.0025 77 0 2022-09-30 LOW
Allworth Financial, L.P. Investment Advisor 0.0021 65 0 2022-09-30 MED
BofA Global Research (US) Research Firm 0.0014 44 -7382 2022-09-30 LOW
Gradient Investments LLC Investment Advisor 0.001 31 0 2022-09-30 MED
Wells Fargo Bank, N.A. Bank and Trust 0.0007 21 0 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.0001 2 -2 2022-09-30 LOW
HBC Financial Services, PLLC Investment Advisor 0.0001 2 2 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Sonoma Pharma Company profile

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing hypochlorous acid (HOCl) products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. It also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The Company sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Sonoma Pharmaceuticals Inc revenues decreased 37% to $10.3M. Net loss before extraordinary items increased 81% to $2.1M. Revenues reflect Latin America segment decrease of 76% to $1.4M, United States segment decrease of 31% to $3.9M. Higher net loss reflects Interest Income decrease of 77% to $3K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.59 to -$0.87.

Equity composition

Common Stock $.0001 Par, 02/11, 100M auth., 26,486,922 issd. Insiders & strategic holders own 10.03%. IPO : 1/07, 3.5M shares @ $8 by RothCapital Partners, Brookstreet Securities Corporation and Maxim Group LLC. 03/13, 1-for-7 reverse stock split.

Industry: Pharmaceuticals (NEC)

5445 CONESTOGA COURT, SUITE 150
BOULDER
COLORADO 80301
US

Income Statement

People also watch

BTC/USD

17,112.00 Price
+0.650% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

US100

11,572.10 Price
-1.890% 1D Chg, %
Long position overnight fee -0.0172%
Short position overnight fee 0.0062%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

5.41 Price
-3.310% 1D Chg, %
Long position overnight fee 0.0411%
Short position overnight fee -0.0662%
Overnight fee time 22:00 (UTC)
Spread 0.005

Oil - Crude

74.79 Price
-3.560% 1D Chg, %
Long position overnight fee -0.0096%
Short position overnight fee -0.0057%
Overnight fee time 22:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading